Lucia Masarova, MD, assistant professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, discusses results from the SURPASS-ET study at the 2025 European Hematology Association Congress in Milan.
The SURPASS-ET study evaluated ropeginterferon against anagrelide in a double blind setting for high-risk essential thrombocythemia (ET) patients refractory after hydroxyurea. Ropeginterferon is not approved to treat patients with ET.
“Very exciting result here in the space…,” Dr. Masarova said. “We’re looking forward to more data from essential thrombocythemia results on interferon.”
